View Report
October 16, 2025
Batch #SLUPHD6
Measured Result
534.91 mcg/tablet
106.98% of label claim
Dragon Pharma
Dragon Pharma
Latest Laboratory Result
534.91 mcg/tablet
October 16, 2025 · 106.98% of label claim
View
SLU-PP-332
Product Information
Compound Details
Active Substance
SLU-PP-332
Pan-ERR agonist (estrogen-related receptor agonist)
500 mcg/tablet
Strength
500 mcg/tablet
Package
100 Tablets
50 mg total labeled content
Form
Oral Tablet
Drug Class
Research Compound / ERR Agonist
Manufacturer
Dragon Pharma
Chemical Formula
C18H14N2O2
$75.00
Shipping :
International
U.S. Domestic
Product Overview
SLU-PP-332 by Dragon Pharma
SLU-PP-332 is an oral tablet manufactured by Dragon Pharma, containing 500 mcg of SLU-PP-332 per tablet in a 100-tablet package.
SLU-PP-332 Oral
SLU-PP-332 is a synthetic small-molecule pan-agonist of the estrogen-related receptors (ERRα, ERRβ, and ERRγ). ERRα is a transcription factor that regulates genes controlling mitochondrial biogenesis, oxidative phosphorylation, and fatty acid oxidation. By activating these receptors, SLU-PP-332 has been shown in preclinical research to mimic some of the metabolic adaptations associated with aerobic exercise, including increased energy expenditure and enhanced fatty acid metabolism.
In animal studies, SLU-PP-332 administration produced significant increases in running endurance, reduced fat mass accumulation, and improved insulin sensitivity in mouse models of obesity and metabolic syndrome. The compound has also been investigated for its cardioprotective effects, with research showing that ERR agonism improved cardiac function and increased survival in a pressure overload-induced heart failure model. SLU-PP-332 is not approved for human use and remains a research compound only.
In non-medical bodybuilding and biohacking contexts, SLU-PP-332 is discussed as a potential "exercise mimetic" for its effects on mitochondrial function and fat oxidation. Published dosing discussions reference a wide range, with some podcast commentary noting that the reported dosing range spans a thousandfold and that only one end of that range does anything. Forum discussions reference oral doses ranging from 250 mcg to 1,500 mcg daily, with some users reporting effects at higher doses. The 500 mcg strength of Dragon Pharma's SLU-PP-332 aligns with commonly referenced retail dose points.
Key Benefits of SLU-PP-332
- Pan-ERR agonist targeting estrogen-related receptors alpha, beta, and gamma
- Preclinical research demonstrates increased mitochondrial biogenesis and fat oxidation
- Studied for exercise-mimetic effects on endurance and metabolic function
- Oral tablet format for convenient administration
- 500 mcg strength aligns with commonly referenced dose points
Formulation
Oral Tablet Format
SLU-PP-332 is supplied as an oral tablet containing 500 mcg of SLU-PP-332 per tablet. Oral administration allows for convenient dosing without the need for injection equipment.
Product Profile
SLU-PP-332 Profile
SLU-PP-332 is a synthetic pan-agonist of the estrogen-related receptors (ERRα, ERRβ, ERRγ) that has demonstrated exercise-mimetic and metabolic effects in preclinical research.
Pan-ERR Agonist (Research Compound)
SLU-PP-332 belongs to the class of estrogen-related receptor (ERR) agonists. ERRs are a subfamily of nuclear receptors that share structural homology with estrogen receptors but do not bind estrogen. ERRα, the most studied isoform, is highly expressed in tissues with high energy demands, including skeletal muscle, heart, and brown adipose tissue. SLU-PP-332 activates all three ERR isoforms with EC50 values of 98 nM for ERRα, 230 nM for ERRβ, and 430 nM for ERRγ.
The downstream effects of ERR activation include upregulation of PGC-1α, a master regulator of mitochondrial biogenesis, and increased expression of genes involved in fatty acid oxidation and oxidative phosphorylation. In mouse studies, SLU-PP-332 administration at 50 mg/kg twice daily increased running endurance by 70% and running distance by 45% compared to untreated controls. Treated mice also showed reduced fat mass accumulation, with diet-induced obese mice gaining 10 times less fat than untreated controls over 28 days.
The pharmacokinetic properties of SLU-PP-332 include a molecular weight of 290.3 g/mol and a chemical formula of C18H14N2O2. The compound is not water-soluble, which may affect oral bioavailability depending on formulation. In vitro metabolism studies have identified multiple metabolites formed through oxidation and glucuronidation pathways.
Research Status
Preclinical Investigation Only
SLU-PP-332 has been studied extensively in animal models but has not been approved for human use. No human clinical trials have established safety or efficacy. All information is derived from preclinical research.
SLU-PP-332 vs Other Dragon Pharma Preparations
Dragon Pharma offers a range of compounds relevant to metabolic and mitochondrial support. SLU-PP-332 is positioned as a research compound, distinct from traditional fat loss agents and performance enhancers.
For mitochondrial support research, Dragon Pharma offers MOTS-C and SS-31, which target different aspects of mitochondrial function. For thermogenic and fat loss approaches, Clenbuterol and T3 are commonly referenced. SLU-PP-332's ERR-agonist mechanism represents a distinct pathway from these compounds.
Laboratory Testing
SLU-PP-332 Lab Reports
Published laboratory reports for SLU-PP-332 are shown below with the test date, measured content and percentage of the product's 500 mcg label claim.
View Report
Laboratory results apply to the specific tested sample represented in each published report and should not be interpreted as a measurement of every tablet or production batch.
Dosage & Usage
SLU-PP-332 Dosage & Usage
The information below is provided for educational reference only. SLU-PP-332 is a research compound that has not been approved for human use. No human clinical trials have established safety, efficacy, or appropriate dosing. Non-medical use falls outside any approved indications.
Typical Dosage Ranges
Because SLU-PP-332 has not entered human clinical trials, no established dosage ranges exist. In non-medical bodybuilding and biohacking contexts, oral doses ranging from 250 mcg to 1,500 mcg daily are commonly referenced, with some users reporting effects at higher doses. A podcast discussion noted that the reported dosing range spans a thousandfold and that only one end of that range does anything. Such use is entirely experimental and falls outside any approved indications.
| Use Case | Common Reference Range | Frequency |
|---|---|---|
| Preclinical research (animal) | 50 mg/kg | Twice daily (injection) |
| Non-medical (low reference) | 250 mcg | Once daily |
| Non-medical (higher reference) | 500–1,500 mcg | Once daily or divided |
These figures are derived from non-medical community discussions and do not represent established human dosing. No clinical safety or efficacy data exists for any human dose of SLU-PP-332.
Stacking & Cycle Considerations
SLU-PP-332 is not an anabolic compound and is not stacked for muscle-building purposes. In non-medical contexts, it is occasionally referenced alongside other mitochondrial or metabolic support compounds. Dragon Pharma offers MOTS-C and SS-31 as research compounds that target different aspects of mitochondrial function. For thermogenic fat loss approaches, Clenbuterol is commonly referenced.
Because SLU-PP-332 has no established human safety profile, cycle structure and support compounds remain entirely speculative. Any use should be considered experimental.
Managing Side Effects
No human safety data exists for SLU-PP-332. Adverse effects observed in animal studies were not reported as significant at the doses used, but this does not establish safety in humans. The compound's effects on estrogen-related receptor signaling raise theoretical concerns about hormonal and reproductive effects that have not been characterized. Individuals should be aware that any human use is entirely experimental.
Post-Cycle Therapy
SLU-PP-332 is not part of standard post-cycle therapy, and no PCT protocols have been established for this compound. PCT compounds such as Clomid and Nolvadex address the hypothalamic-pituitary-gonadal axis rather than ERR signaling. SLU-PP-332's research focus has been on metabolic and mitochondrial endpoints, not hormonal recovery.
Important
Research Compound Only
SLU-PP-332 has not been approved for human use and no human clinical trials have been conducted. The information above is for educational reference and does not constitute medical advice. Any human use is entirely experimental and may carry unknown health risks.
Safety & Information
SLU-PP-332 Safety Information
SLU-PP-332 is a research compound that has not been evaluated in human clinical trials. No safety data exists for human use.
Important Safety Information
SLU-PP-332 has not been approved by the FDA or any other regulatory agency for human use. It is a research chemical that has been studied only in preclinical (animal and cell culture) models. The absence of human clinical trials means that no established safe dose, toxicity profile, or long-term safety data exists.
Important
Not for Human Use
SLU-PP-332 is sold for research purposes only. It is not a dietary supplement, medication, or approved therapeutic agent. Human consumption is not recommended and may pose unknown health risks. Product quality does not establish that human use is safe or appropriate.
Potential Adverse Effects
No human adverse effect data exists for SLU-PP-332. In animal studies, the compound was administered at 50 mg/kg twice daily without reported severe adverse effects, but animal tolerability does not predict human safety. Theoretical concerns include potential effects on estrogen-related receptor signaling, which could influence reproductive and metabolic pathways that have not been characterized in humans.
The compound's chemical structure includes a hydrazide moiety. Podcast commentary has referenced "hydrazide risk" in discussions of SLU-PP-332 and its analog SLU-PP-915. The toxicological significance of this structural feature in humans has not been established.
SLU-PP-332 is not water-soluble, which may affect its absorption and distribution depending on the formulation used. In vitro metabolism studies have identified multiple metabolites, but their biological activity and potential toxicity are unknown.
Conditions Requiring Medical Evaluation
Because no human safety data exists, there are no established contraindications or conditions requiring medical evaluation. Individuals with pre-existing medical conditions, those taking prescription medications, and those with concerns about hormonal or metabolic health should consult a qualified healthcare professional before considering any experimental compound.
Monitoring During Therapy
No monitoring protocols have been established for SLU-PP-332 because it has not entered human clinical trials. In research settings, animal studies have monitored parameters including body weight, fat mass, glucose tolerance, and running endurance. No human monitoring guidelines exist.
Product Care
Storage & Handling
Keep the product securely stored and protected from conditions that could compromise the tablets or packaging. Inspect the product before use and do not use if it appears damaged or otherwise abnormal. Keep all research compounds out of the reach of children. SLU-PP-332 powder is reported to be stable when stored at -20°C, though tablet formulations may have different storage requirements.
Further Research Information
Shipping & Authenticity
Shipping & Product Authenticity
SLU-PP-332 is supplied through the official Dragon Pharma distribution chain and shipped in original manufacturer packaging with discreet, privacy-focused handling.
USA Domestic 3–5 business days
International 10–15 business days
Order Processing 24–48 business hours
Tracking Provided after dispatch
Direct Supply
Discreet Delivery & Original Packaging
The outer shipping package remains discreet, with privacy-focused handling and no unnecessary external product details. Products are supplied through the official Dragon Pharma distribution chain.
What to Expect
- Orders are processed after payment confirmation
- USA Domestic shipping is typically faster when local stock is selected
- International orders include tracking, though update frequency may vary by destination
- Multiple warehouses may result in separate shipments when applicable
Authenticity Verification
To verify your SLU-PP-332 product, use the security code on the packaging and cross-check it on the Dragon Pharma official site. Official Dragon Pharma presentation, batch-linked lab proof, and original packaging help reinforce product legitimacy and buyer confidence.
Storage
SLU-PP-332 Storage
Proper storage conditions help preserve tablet integrity and stability throughout shelf life.
Recommended Conditions
Store in a cool, dry place at controlled room temperature (15–25°C). Protect from excessive heat, moisture, and direct light. Keep the tablets in their original packaging until use.
Do not use if the packaging appears damaged or if the tablets show signs of deterioration. Keep out of reach of children. For research-grade powder, storage at -20°C is recommended, though tablet formulations may have different stability profiles.
Quick Reference
Do & Don't
- Do store at 15–25°C
- Do keep in original packaging
- Do inspect before use
- Don't expose to excessive heat
- Don't store in humid environments
- Don't use if packaging is compromised
Frequently Asked Questions
SLU-PP-332 FAQ
Answers to common questions about SLU-PP-332, ERR agonists, product strength and laboratory testing.
What is SLU-PP-332 used for?
SLU-PP-332 is a research compound that has been studied in preclinical models for its effects on mitochondrial function, fat oxidation, and endurance capacity. It has not been approved for human use and is sold for research purposes only. In non-medical contexts, it is discussed as a potential exercise mimetic.
How often should SLU-PP-332 be taken?
No established human dosing exists for SLU-PP-332. In non-medical community discussions, oral doses of 250 mcg to 1,500 mcg daily are referenced, with some users reporting effects at higher doses. A podcast discussion noted that the reported dosing range spans a thousandfold. All human use is experimental.
Does SLU-PP-332 require PCT?
What does SLU-PP-332 do?
SLU-PP-332 is a pan-agonist of estrogen-related receptors (ERRα, ERRβ, ERRγ). Activation of these receptors upregulates genes involved in mitochondrial biogenesis, oxidative phosphorylation, and fatty acid oxidation. In animal studies, this led to increased endurance, reduced fat mass, and improved insulin sensitivity.
How long does SLU-PP-332 take to work?
No human data exists on the time course of SLU-PP-332 effects. In animal studies, metabolic and endurance effects were observed over days to weeks of treatment. The compound's pharmacokinetic properties in humans have not been characterized.
Is SLU-PP-332 the best exercise mimetic?
There is no established "best" exercise mimetic, and SLU-PP-332 has not been compared to other compounds in human trials. It is a research tool for studying ERR biology. Its preclinical effects on endurance and metabolism have generated interest, but human relevance remains unknown.
What is the difference between SLU-PP-332 and MOTS-C?
SLU-PP-332 and MOTS-C work through different mechanisms. SLU-PP-332 activates ERR nuclear receptors to upregulate mitochondrial gene expression, while MOTS-C is a mitochondrial-derived peptide that activates AMPK signaling. Both are research compounds with distinct biological targets.
What is the difference between SLU-PP-332 and SS-31?
SLU-PP-332 and SS-31 target different aspects of mitochondrial function. SLU-PP-332 activates ERR receptors to promote mitochondrial biogenesis and fatty acid oxidation, while SS-31 is a mitochondria-targeted peptide that binds to cardiolipin and protects mitochondrial structure. They are not interchangeable.
Is 500 mcg of SLU-PP-332 a lot?
No human dosing standards exist for SLU-PP-332. In non-medical community discussions, 500 mcg is within the commonly referenced range of 250 mcg to 1,500 mcg daily. However, this does not establish safety or efficacy. The 500 mcg strength of Dragon Pharma's SLU-PP-332 aligns with commonly referenced retail dose points.
What strength is SLU-PP-332?
SLU-PP-332 is labeled at 500 mcg of SLU-PP-332 per tablet. It is supplied in a 100-tablet package, giving 50 mg of total labeled SLU-PP-332 content.
Is SLU-PP-332 lab tested?
Yes. A published laboratory report dated October 16, 2025 measured SLU-PP-332 at 534.91 mcg/tablet, equivalent to 106.98% of its 500 mcg label claim. The batch number for this report was #SLUPHD6. The complete report can be viewed in the Lab Reports tab.
Has SLU-PP-332 been tested in humans?
No. SLU-PP-332 has been studied only in preclinical models, including cell culture and mouse studies. No human clinical trials have been conducted, and no human safety or efficacy data exists. The compound is not approved for human use.
Related Offers
Lab Tested
Domestic & International
Dragon Pharma, Europe
Product Information Compound Details
Active Substance Testosterone Cypionate Long-acting testosterone ester
250 mg/mLStrength 250 mg/mL
Package 10 mL Vial 2,500 mg total labeled content
Form Oil-Based Injectable (MCT Oil)
Estimated Half-Life Approximately 8 Days
Drug Class Androgen & Anabolic Steroid
Manufacturer Dragon Pharma
$53.00
Lab Tested
Domestic & International
Dragon Pharma, Europe
Product Information Compound Details
Active Substance Testosterone Enanthate Long-acting testosterone ester
250 mg/mLStrength 250 mg/mL
Package 10 mL Vial 2,500 mg total labeled content
Form Oil-Based Injectable (MCT Oil)
Estimated Half-Life Approximately 4.5–7 Days
Drug Class Androgen & Anabolic Steroid
Manufacturer Dragon Pharma
$46.00
Lab Tested
Domestic & International
Buy 5+ for $56.73 and save $21.35
Dragon Pharma, Europe
Product Information
Compound Details
Active Substance
Tadalafil Citrate
Long-acting PDE5 inhibitor
20 mg/tablet
Strength
20 mg/tablet
Package
100 Tablets
2,000 mg total labeled content
Form
Oral Tablet
Drug Class
PDE5 Inhibitor
Manufacturer
Dragon Pharma
Half-Life
Approximately 17.5 Hours
$61.00
Lab Tested
Domestic & International
Dragon Pharma, Europe
Product Information
Compound Details
Active Substance
Clenbuterol Hydrochloride
Beta-2 adrenergic agonist
40 mcg/tablet
Strength
40 mcg/tablet
Package
100 Tablets
4,000 mcg total labeled content
Form
Oral Tablet
Half-Life
Approximately 35 Hours
Drug Class
Beta-2 Agonist
Manufacturer
Dragon Pharma
$44.00